Alnylam Going After Alexion's Soliris In PNH, Eyes Roche In Hemophilia

At an investor day, the RNAi firm outlined Phase I programs in paroxysmal nocturnal hemoglobinuria, hemophilia and hepatic porphyria, and said it is using a de-risked drug development methodology.